Is Johnson Health Tech. Co., Ltd. (TPE:1736) Worth NT$65.7 Based On Its Intrinsic Value?

Today we’ll do a simple run through of a valuation method used to estimate the attractiveness of Johnson Health Tech. Co., Ltd. (TPE:1736) as an investment opportunity by taking the expected future cash flows and discounting them to today’s value. This is done using the Discounted Cash Flow (DCF) model. Don’t get put off by the jargon, the math behind it is actually quite straightforward.

We generally believe that a company’s value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Johnson Health Tech

Crunching the numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second ‘steady growth’ period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren’t available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today’s dollars:

10-year free cash flow (FCF) estimate

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Levered FCF (NT$, Millions) NT$852.0m NT$991.0m NT$1.09b NT$1.17b NT$1.23b NT$1.28b NT$1.31b NT$1.34b NT$1.37b NT$1.39b
Growth Rate Estimate Source Analyst x1 Analyst x1 Est @ 9.93% Est @ 7.17% Est @ 5.23% Est @ 3.87% Est @ 2.92% Est @ 2.26% Est @ 1.8% Est @ 1.47%
Present Value (NT$, Millions) Discounted @ 8.7% NT$784 NT$839 NT$849 NT$837 NT$810 NT$774 NT$733 NT$690 NT$646 NT$603

(“Est” = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = NT$7.6b

The second stage is also known as Terminal Value, this is the business’s cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country’s GDP growth. In this case we have used the 10-year government bond rate (0.7%) to estimate future growth. In the same way as with the 10-year ‘growth’ period, we discount future cash flows to today’s value, using a cost of equity of 8.7%.

Terminal Value (TV)= FCF2029 × (1 + g) ÷ (r – g) = NT$1.4b× (1 + 0.7%) ÷ 8.7%– 0.7%) = NT$18b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= NT$18b÷ ( 1 + 8.7%)10= NT$7.6b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is NT$15b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of NT$65.7, the company appears reasonably expensive at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

TSEC:1736 Intrinsic value May 4th 2020
TSEC:1736 Intrinsic value May 4th 2020

The assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don’t agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company’s future capital requirements, so it does not give a full picture of a company’s potential performance. Given that we are looking at Johnson Health Tech as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we’ve used 8.7%, which is based on a levered beta of 1.284. Beta is a measure of a stock’s volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to “what assumptions need to be true for this stock to be under/overvalued?” If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price to differ from the intrinsic value? For Johnson Health Tech, We’ve put together three pertinent factors you should further research:

  1. Risks: Every company has them, and we’ve spotted 2 warning signs for Johnson Health Tech (of which 1 is a bit concerning!) you should know about.
  2. Future Earnings: How does 1736’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the TSEC every day. If you want to find the calculation for other stocks just search here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.